Molecular Partners share#snapshot#suffix 111300183 / US60853G1067
3.88
USD
-0.06
USD
-1.52 %
09.10.2026
BTT
| prices + charts + realtime | news + analysis | fundamental | company | corresponding shares | action | |
|---|---|---|---|---|---|---|
| price + Chart | chart (large) | news + ad-hoc | balance sheet/p&l | fixed dates | certificates | portfolio#add_instrument_to#depot |
| times + sale | chart comparison | analysis | detailnavigation#shares#estimates | profile | portfolio#add_instrument_to#watchlist | |
| stock exchange | realtime push | stock price appreciation potential | dividend/annual shareholders' meeting | |||
| historic | analysis | |||||
prices + charts + realtime
news + analysis
fundamental
company
corresponding shares
Aktie Analysen & Prognosen
Fundamentalanalyse
| Preis | Mrk. Kap. in Mrd. $ | revid. Gew. Prognose | Bewertung | Wachstum / KGV | KGV 2020 | langfrist. Wachstum | Div. Rend. | mittelfrist. Mkt Trend | rel. 4 Wo. Perform. |
|---|---|---|---|---|---|---|---|---|---|
| 3.81 USD | % | % | % |
| revid. Gewinn Prognose | ||||
| Bewertung | ||||
| relative 4 Wochen Performance | % | |||
| mittelfristiger Markttrend | ||||
| Markt Kapitalisierung in Mrd. $ | Grosser Marktwert | Mit einer Marktkapitalisierung von > $5 Mrd., ist ein hoch kapitalisierter Titel. | ||
| Wachstum / KGV | ||||
| KGV | ||||
| langfristiges Wachstum | % | Wachstum heute bis p.a. | Die durschnittlichen jährlichen Wachstumsraten gelten für die Gewinne von heute bis | |
| Anzahl der Analysten | Nur von wenigen Analysten verfolgt | In den zuräckliegenden sieben Wochen haben durchschnittlich Analysten eine Schätzung des Gewinns pro Aktie für diesen Titel abgegeben. | ||
| Dividenden Rendite | % | |||
| Zeichenerklärung | ||
|---|---|---|
| revidierte Gewinn Prognose | = , | = , |
| Bewertung | = , | = , , |
| relative 4 Wochen Performance | = negative Werte | = positive Werte |
| mittelfristiger Markttrend | = , | = , |
Risikoanalyse
| Preis | Mrk. Kap. in Mrd. $ | Bear Market Faktor | Bad News Faktor | Beta 1 Jahr | Korrelation |
|---|---|---|---|---|---|
| 3.81 USD |
| Risiko | |||
| Bear Market | |||
| Bad News | |||
| Beta | Die Aktie tendiert dazu, pro 1% Indexbewegung mit einem Ausschlag von % zu reagieren. | ||
| Korrelation 365 Tage | |||
shares#estimates#headline Molecular Partners in USD
| 2026 | 2027 | 2028 | 2029 | 2030 | |
|---|---|---|---|---|---|
| shares#estimates#column#sales | 0.00 | 0.00 | 0.00 | 0.00 | 54.81 |
| shares#estimates#column#dividendspershare | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| shares#estimates#column#dividendyield | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| shares#estimates#column#earningpersharebasic | -1.73 | -1.54 | -1.55 | -1.10 | -0.67 |
| shares#estimates#column#pricetoearningsratio | -2.20 | -2.47 | -2.45 | -3.48 | -5.66 |
| shares#estimates#column#earningsbeforeinterestandtaxes | -67.68 | -71.35 | -79.95 | -98.17 | -52.32 |
| shares#estimates#column#earningsbeforeinteresttaxesdepreciationamortization | -66.39 | -73.08 | -92.79 | -108.48 | -79.21 |
| shares#estimates#column#netprofit | -65.30 | -69.37 | -78.79 | -97.25 | -47.30 |
| shares#estimates#column#netprofitadjusted | |||||
| shares#estimates#column#pretaxprofit | -67.26 | -68.51 | -71.00 | -84.70 | -52.32 |
| shares#estimates#column#pretaxprofitreported | |||||
| shares#estimates#column#earningpersharenongaap | |||||
| shares#estimates#column#earningpersharereported | -1.52 | -1.11 | -1.15 | -1.10 | -0.67 |
| shares#estimates#column#grossincome | 0.00 | 0.00 | 0.00 | 0.00 | |
| shares#estimates#column#cashflowfrominvesting | -1.25 | -1.25 | -1.25 | -2.49 | |
| shares#estimates#column#cashflowfromoperations | -78.65 | -92.32 | -41.11 | ||
| shares#estimates#column#cashflowfromfinancing | 95.01 | 211.28 | |||
| shares#estimates#column#cashflowpershare | |||||
| shares#estimates#column#freecashflow | |||||
| shares#estimates#column#freecashflowpershare | |||||
| shares#estimates#column#bookvaluepershare | |||||
| shares#estimates#column#netdebt | |||||
| shares#estimates#column#researchanddevelopment | 48.12 | 50.91 | 59.10 | 73.96 | 61.04 |
| shares#estimates#column#capitalexpenditure | 2.49 | 2.49 | 2.49 | 2.49 | 2.49 |
| shares#estimates#column#sellinggeneralandadministrativeexpense | 19.57 | 20.02 | 21.26 | 24.21 | 36.12 |
| shares#estimates#column#shareholdersequity | 161.43 | 96.17 | 18.92 | 82.68 | 22.19 |
| shares#estimates#column#totalassets | 175.75 | 132.97 | 102.56 | 222.19 | 384.90 |
shares#estimates#footer
Molecular Partners AG (spons. ADRs) Aktie Analysen
error#message#nodata